Table 5.
Cancer type | Country, no. of participants, treatment stage | Study design | Physiological | Psychosocial & cultural | Economic & environmental | Reference | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(A) Feeling well, & (B) Symptom management strategies | (A) Positive previous experience, (B) Perceived benefits, (C) Exercise in routine (D) Social support and guidance, & (E)Companionship |
(A) Affordable programs, & (B) Accessible/ tailored amenities | ||||||||||
(A) | (B) | (A) | (B) | (C) | (D) | (E) | (A) | (B) | ||||
Breast | Canada, 9 women, post-ttt | QI | + | + | + | + | + | + | [40] | |||
Canada, 8, during ttt | QI | + | + | + | + | + | + | [49] | ||||
Canada, 12, mixed stages | QI | + | + | [77] | ||||||||
New Zealand, 20 women | FG | + | + | + | [51] | |||||||
Norway, 27, during ttt | FG | + | + | + | [52] | |||||||
Spain, 14 women, post-ttt | QI | + | + | + | + | [99] | ||||||
Sweden, 16, during ttt | QI | + | + | + | [53] | |||||||
Sweden, 29, post-ttt | MM | + | + | + | [123] | |||||||
Sweden, 12, post-ttt | QI | + | [124] | |||||||||
US, 15 women, post ttt | QI | + | + | + | [125] | |||||||
US, 60 women, post-ttt | QI | + (50) | + (97) | + (20) | [54] | |||||||
US, 30 women, during ttt | QI | + | + | [101] | ||||||||
Colo-rectal | Canada, 600, post-ttt | CS | + (10) | + (13) | + (12) | [57] | ||||||
Netherlands, 15, mixed | QI | + | + | + | + | + | + | + | [92] | |||
Sweden, 17 patients | QI | + | + | + | + | + | [59] | |||||
Endometrial | UK, 16 women, post-ttt | QI | + | + | + | [60] | ||||||
Gynecologic | Canada, 239 survivors | MM | + (50) | + (50) | + | + | + | [44] | ||||
Kidney | Canada, 482, post-ttt | CS | + (47) | + (7), | [61] | |||||||
Lung | Australia, 7, post-ttt | FG | + | + | + | + | [63] | |||||
Denmark, 19, post-ttt | QI | + | + | + | + | [64] | ||||||
France, 5 patients | QI | + | + | + | [105] | |||||||
US, 43, during ttt | CS | + (15) | + (11) | + (15) | + (37) | [65] | ||||||
Lung & GI | US, 34 patients | QI | + | + | + | + | + | [107] | ||||
Lymphoma | US, N/A, post-ttt | FG | + | + | [108] | |||||||
Prostate | Australia, 18 men, post-ttt | QI | + | + | [68] | |||||||
Australia, 14 men | QI | + | + | + | [112] | |||||||
England, 16 men, post-ttt | QI | + | + | + | + | + | [113] | |||||
Ireland, 20 men | QI | + | [31] | |||||||||
Variousa | Australia, 15, mixed stages | QI | + | + | + | [70] | ||||||
Australia, 9, during ttt | QI/FG | + | + | + | + | [69] | ||||||
Australia, 102, post-ttt | CS | + | + (99) | + (97) | + (81) | + | [71] | |||||
Australia, 20, during ttt | QI | + | + | [117] | ||||||||
Canada, 30, during ttt | CS | + (63) | + (37) | + | + (32) | + | + (42) | [20] | ||||
Denmark, 33, during ttt | QI | + | + | + | + | + | [118] | |||||
Germany, 905 patients | CS | + | + | + | [76] | |||||||
Ireland, 41, mixed stages | FG | + | + | + | [77] | |||||||
Italy, 12, post-ttt | FG | + | + | + | + | + | + | [78] | ||||
New Zealand, 25, mixed | QI | + | + | + | [81] | |||||||
Sweden, 18, during ttt | FG | + | + | + | + | + | [24] | |||||
UK, 26, mixed stages | FG | + | + | + | + | + | [84] | |||||
UK, 456, post-ttt | CS | + | + | + | + | [43] | ||||||
UK, 19 patients, post-ttt | QI | + | + | + | [37] | |||||||
UK, 12, mixed stages | QI | + | + | + | [36] | |||||||
UK, 16, mixed stages | QI | + | + | [83] | ||||||||
US, 25, post-ttt | FG | + | + | + | + | + | [86] | |||||
US, 20, post-ttt | QI | + | + | + | + | [39] | ||||||
US, 13, mixed stages | QI | + | + | + | [122] |
Abbreviations: CS cross-sectional, FG focus groups, MM mixed-method, N/A non-available, PA physical activity, QI qualitative interview, ttt treatment. a The study included various mixed cancer types